Pfizer weighs strategic alternatives consumer healthcare business

Move comes amid national drug-pricing controversy

Last week, Pfizer increased the list prices of its medications in the United States by an average of 8.8%, according to an article in STAT News. This is the second time this year that the company has boosted prices for its prescription drugs. On January 1, Pfizer’s prices rose an average of 10.4% for 100 of its drugs. The increases, however, do not reflect rebates or discounts.

Pfizer’s move comes amid a growing controversy over prescription drug pricing. The issue exploded last year after two companies—Valeant Pharmaceuticals and Turing Pharmaceuticals—drew fire for their strategies of buying older medications and then jacking up prices by sky-high percentages. Turing, for example, boosted the price of a human immunodeficiency virus treatment by approximately 5,000%—from $13.50 a tablet to $750—shortly after buying the drug. Valeant, meanwhile, hiked the price of the Nitropress heart drug, which is used by hospitals, by 525% on the same day it bought the medication. Those questionable tactics prompted congressional scrutiny.

A Pfizer spokesman told STAT News that, last year, the company paid approximately $4.6 billion in rebates to Medicare, Medicaid, and commercial insurers. “Some of our most widely used medicines, including Lyrica [pregabalin], Xalkori [crizotinib], Ibrance [palbociclib], and Prevnar [pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)], will not have an increase,” he said.

In January, Pfizer confirmed a 9.4% increase for its heavily advertised pain drug Lyrica; a 12.9% increase for the erectile dysfunction drug Viagra (sildenafil); and a 5.0% increase for the breast cancer treatment Ibrance.

Sources: STAT News; June 9, 2016; and Reuters; January 8, 2016.

More Headlines

Humana, UnitedHealthcare, and Some Blues Selected for New Part D Experimental Model
UV Light Robots Cut C. Difficile Transmission by 25%, Study Finds
Hospital saves between $350,000 and $1.5 million annually with no-touch devices
Scientists May Have Discovered Key to Universal Flu Vaccine
Viral binding sites make all the difference
‘Lab Strain’ Hinders Zika Detection in U.S.
Federal government’s cash infusion may not be enough
Report: Seven-Day Readmissions May Be Better Indicator of Quality of Care Than 30 Days Post-Discharge
Most readmissions are determined by community- and household-level factors
U.S. Hospitals and Equipment Aren’t Aging Gracefully
Health care facilities are oldest since 1949
More Pregnant Women Dying in America
Bitter Harvest: Deaths From Drug Scourge Puts More Organs for Transplant in Play

 


Our most popular topics on Managedcaremag.com